Overview

Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and to determine the adequate antihypertensive dosage for later clinical study.

Phase:

Phase 2

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Collaborators:

Asan Medical Center
Cheil General Hospital and Women's Healthcare Center
Cheil General Hospital and Women’s Healthcare Center
Samsung Medical Center
Seoul National University Bundang Hospital
Seoul National University Hospital
Severance Hospital
The Catholic University of Korea
Yonsei University

Treatments:

Antihypertensive Agents